News & Updates

Hypertension in pregnancy: Labetalol extends benefits for pregnancy outcomes
Hypertension in pregnancy: Labetalol extends benefits for pregnancy outcomes
22 Feb 2022 byJairia Dela Cruz

Common blood pressure (BP)-lowering medications in pregnancy cut the risk of severe hypertension, but labetalol has the added advantage of reducing the risks of proteinuria or pre-eclampsia and perinatal death, according to the results of a network meta-analysis.

Hypertension in pregnancy: Labetalol extends benefits for pregnancy outcomes
22 Feb 2022
First-line biologic therapy persists longer than later agents in ankylosing spondylitis
First-line biologic therapy persists longer than later agents in ankylosing spondylitis
22 Feb 2022

Biologic disease-modifying antirheumatic drug (bDMARD) therapy is effective in reducing ankylosing spondylitis (AS) disease activity, reports a study, noting how treatment has persisted for up to 8 years among patients remaining on their first bDMARD, which is longer than on subsequent agents.

First-line biologic therapy persists longer than later agents in ankylosing spondylitis
22 Feb 2022
NOACs preferable over warfarin in AF patients with bioprosthetic valves
NOACs preferable over warfarin in AF patients with bioprosthetic valves
22 Feb 2022
Why do some PCR-negative patients test positive on COVID-19 blood tests?
Why do some PCR-negative patients test positive on COVID-19 blood tests?
22 Feb 2022 byTristan Manalac

Serological assays for the coronavirus disease 2019 (COVID-19) sometimes show contradictory findings when compared with nasopharyngeal swab polymerase chain reaction (PCR) tests, according to a recent Singapore study. In particular, even PCR-negative patients with no known exposure could test positive for antibodies.

Why do some PCR-negative patients test positive on COVID-19 blood tests?
22 Feb 2022
Add-on lenacapavir helps maintain virologic suppression in treatment-naïve PWH
Add-on lenacapavir helps maintain virologic suppression in treatment-naïve PWH
21 Feb 2022 byAudrey Abella

Combining the potent first-in-class capsid assembly inhibitor lenacapavir with other antiretroviral agents led to sustained high rates of virologic suppression in treatment-naïve persons with HIV-1 (PWH) infection, according to the week-54 results of the phase II Calibrate trial.

Add-on lenacapavir helps maintain virologic suppression in treatment-naïve PWH
21 Feb 2022